title: The Cobas® EGFR Mutation Test v2 assay.
abstract: Paul Brown speaks to Gemma Westcott, Commissioning Editor: Paul Brown has served as the Head of Roche Molecular Diagnostics at Roche Diagnostics Corporation since February 2010 having previously held a variety of positions within Roche Pharma. After completing his doctorate in organic chemistry he was awarded a post-doctoral fellowship at the California Institute of Technology in Pasadena, CA, USA, but soon returned to his native UK to join Roche Pharma Research. Paul's first post within Roche was as group leader, doing drug discovery and making new small molecule drugs, but later moved into the business part of the company. Since then, he has enjoyed roles such as lifecycle leader for brands such as Tamiflu(®) and Xenical, vice president of sales and marketing of the pharmaceutical division and most recently general manager of Roche Pharma, Sweden.
authors.affiliation: Roche Molecular Diagnostics, 4300 Hacienda Drive, Pleasanton, CA 94588, USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Brown
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D005820:Genetic Testing / Q000379:methods* / Q000592:standards; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D058990:Molecular Targeted Therapy; D009154:Mutation; D018579:Patient Selection; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011933:Reagent Kits, Diagnostic / Q000600:supply & distribution; D012106:Research
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011933:Reagent Kits, Diagnostic; D066246:ErbB Receptors
keywords: Cobas® EGFR Mutation Test v2; in vitro diagnostics; lung cancer; oncology